Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pulse Biosciences ( (PLSE) ) has shared an announcement.
On January 14, 2025, Pulse Biosciences released an updated investor presentation on their website highlighting recent advancements in their cardiac treatment product line. This update is intended to inform investors and analysts about the progress in their product development programs, potentially impacting company operations and stakeholder decisions.
More about Pulse Biosciences
Pulse Biosciences, Inc. operates in the medical technology industry, focusing on the development of proprietary bioelectric treatments. Their primary products include the CellFX™ nsPFA™ 360 Cardiac Catheter, CellFX nsPFA Cardiac Clamp, and CellFX nsPFA Percutaneous Electrode, targeting advancements in cardiac treatment technologies.
YTD Price Performance: 1.29%
Average Trading Volume: 168,305
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.14B
For detailed information about PLSE stock, go to TipRanks’ Stock Analysis page.
